CD8+ T cell recall cytotoxicity during antiretroviral therapy is associated with limited HIV-1 reservoir size and activity

This study reveals that a subset of people with HIV on antiretroviral therapy possess highly functional CD8+ T cells capable of targeting autologous viral reservoirs, a phenomenon associated with smaller, less active reservoirs and the attenuation of viral rebound during treatment interruption, thereby highlighting the potential of immunotherapies to achieve durable HIV remission.

The Gist

The Big Picture: A "Sleeping" Enemy and a Waking Guard

Imagine your body is a fortress, and HIV is a spy that has managed to sneak inside and hide in the walls. Even when you take medication (Antiretroviral Therapy, or ART) that keeps the spy from causing trouble, it doesn't leave. It just goes to sleep in a "reservoir" (a hidden stash of viral DNA). If you stop the medication, the spy wakes up, multiplies, and takes over again.

For decades, scientists thought that once people started taking HIV medication later in their infection (chronic stage), their immune system's "special forces" (CD8+ T cells) were too tired and broken to ever fight the virus again. They believed these soldiers were permanently exhausted.

This paper flips that story on its head.

The researchers found that in about 17% of people who have been on medication for a long time, their immune system's special forces are not broken. They are actually awake, sharp, and ready to fight. When the virus tries to wake up, these soldiers can remember the enemy, multiply rapidly, and attack.

---

The Story in Three Acts

Act 1: The Surprise Discovery (The "Sleeping Giants")

The researchers looked at 60 people living with HIV who had been on medication for an average of 19 years. They tested their immune cells to see if they could recognize and kill the specific parts of the virus hiding in their bodies.

• The Expectation: Most people's immune cells were like a sleepy guard dog that had forgotten how to bark. They couldn't recognize the virus or attack it.
• The Surprise: In 17% of the group, the immune cells were like elite special forces. They could recognize the virus, multiply rapidly (proliferate), and kill infected cells (cytotoxicity).
• The Analogy: Imagine a library where most books are locked in a cage. For most people, the key to the cage is lost. But for this 17%, the key is still in their pocket, and they know exactly how to use it.

Act 2: The Connection (Smaller Hiding Spots)

The researchers noticed something interesting: The people with these "elite" immune cells had smaller virus reservoirs.

• The Analogy: Think of the virus reservoir as a hoard of gold coins hidden in a cave.
  • People with "sleepy" immune cells had a massive cave full of gold (a large virus reservoir).
  • People with "elite" immune cells had a tiny, almost empty cave (a small virus reservoir).
• What this means: It suggests that these active immune cells might be constantly patrolling the cave, eating the gold coins (killing the virus) as they appear, keeping the reservoir small. They aren't eradicating the virus completely yet, but they are keeping it in check better than others.

Act 3: The Experiment (Stopping the Meds)

To see what happens when the virus wakes up, one participant (let's call him "Hero") stopped his medication under strict medical supervision. This is called an "Analytical Treatment Interruption" (ATI).

• The Event: The virus started to wake up and multiply (viral rebound).
• The Reaction: Hero's immune system didn't panic. His "elite" soldiers remembered the virus.
  • First, a different type of cell (NK cells) rushed in to help.
  • Then, the specific "elite" CD8+ T cells multiplied 2.5 times their original number.
  • They transformed from "sleeping guards" into "active warriors," releasing weapons (perforin and granzyme) to kill the infected cells.
• The Result: The virus started to rise, but then it hit a wall. The immune response kicked in and slowed the virus down significantly before the doctors restarted the medication.
• The Analogy: It's like a burglar breaking into a house. The alarm goes off (viral rebound). The burglar starts running around, but then the homeowner's security team (the immune cells) wakes up, multiplies, and chases the burglar down, slowing him down before the police (the medication) arrive to finish the job.

Why Does This Matter?

1. Hope for a Cure: This study shows that the immune system isn't always "broken" in chronic HIV infection. It can be restored or preserved.
2. The "17%" Clue: Since 17% of people naturally have these strong responses, scientists now know that it is possible to get the immune system to this level.
3. Future Treatments: The goal of HIV cure research is to find a way to wake up everyone's immune system, not just the lucky 17%. If we can combine medication with therapies that boost these "elite" soldiers (like vaccines or immunotherapies), we might be able to keep the virus suppressed without needing daily pills.

The Bottom Line

This paper tells us that even after years of living with HIV, a significant number of people still have a powerful, functional immune army waiting in the wings. While this army couldn't stop the virus from waking up entirely on its own, it was strong enough to slow the virus down and keep the "hiding spots" small.

The challenge for the future is to figure out how to train everyone's immune system to be this strong, turning the "sleeping guards" into "elite special forces" for all people with HIV.

Technical Summary

1. Problem Statement

Despite the efficacy of Antiretroviral Therapy (ART) in suppressing viral replication, HIV-1 persists in a latent reservoir, leading to viral rebound upon treatment interruption. While spontaneous HIV-1 controllers (less than 1% of infected individuals) naturally control the virus via robust, proliferative, and cytolytic CD8+ T cell responses, most people with HIV (PWH) on ART exhibit impaired virus-specific CD8+ T cell function.

• Knowledge Gap: It remains unclear whether a subset of PWH treated during chronic infection retains functional, recall-capable CD8+ T cells capable of targeting autologous proviral epitopes. Furthermore, the relationship between these functional immune responses and the size/activity of the HIV-1 reservoir, as well as their impact on viral rebound dynamics, is not well-defined.

2. Methodology

The study utilized a multi-modal approach involving a cohort of 60 virologically suppressed PWH from the HIV Eradication and Latency (HEAL) study, who initiated ART during chronic infection (median 19 years on ART).

• Immune Profiling:
  • Epitope Mapping: Used IFN-γ ELISPOT with HLA-optimal peptides to map HIV-specific CD8+ T cell responses.
  • Functionality Assays: Measured proliferation via CFSE dilution and recall cytotoxicity using an Expanded Antigen-Specific Elimination Assay (EASEA) after 6 days of in vitro antigen re-exposure.
  • Autologous Validation: Sequenced proviral DNA from CD4+ T cells to identify autologous epitope variants. Performed cross-recognition assays to distinguish between functional responses against the actual reservoir and responses against mutated (escaped) epitopes.
  • Phenotyping: Used peptide-HLA (pHLA) tetramers and flow cytometry to assess memory, activation, and exhaustion markers (e.g., PD-1, TCF-1, CD38).
• Reservoir Quantification: Measured total HIV-1 DNA, intact proviral DNA (via CS-IPDA), and cell-associated unspliced RNA (usRNA) to assess reservoir size and transcriptional activity.
• Analytical Treatment Interruption (ATI) Case Study: One participant (H047) underwent a closely monitored ATI.
  • Longitudinal Monitoring: Weekly viral load and bi-weekly PBMC collection.
  • Single-Cell Multiomics: Performed CITE-seq (RNA + surface protein + TCR/BCR) on 37,462 PBMCs across six time points to track clonal expansion and differentiation.
  • Targeted Analysis: Sorted and sequenced Gag-specific CD8+ T cells to resolve clonotypic dynamics during rebound.

3. Key Contributions

• Prevalence of Functional Memory: Identified that 17% of PWH treated during chronic infection possess highly functional, proliferative, and cytolytic CD8+ T cells targeting autologous (non-escaped) HIV-1 epitopes. This prevalence is >50-fold higher than spontaneous controllers.
• Reservoir Correlation: Established a direct association between high CD8+ T cell recall cytotoxicity and significantly smaller, less transcriptionally active HIV-1 reservoirs.
• In Vivo Dynamics: Provided high-resolution temporal data showing that recall cytotoxicity does not prevent viral rebound but coincides with the attenuation of rebound viremia.
• Clonal Plasticity: Demonstrated that distinct T cell clonotypes (progenitor-exhausted vs. quiescent memory) expand in parallel during viral recrudescence, challenging the notion that only specific phenotypic states drive control.

4. Key Results

A. Prevalence and Functionality of CD8+ T Cells

• Proliferation: 17 of 60 participants (28%) showed at least one proliferative response. Of the 221 total responses mapped, 21 (9.5%) exhibited proliferation levels comparable to spontaneous controllers (≥5% CFSE dilution).
• Autologous Recognition: Sequencing revealed that 13 of the 21 proliferative responses targeted autologous variants.
  • 5 responses were "escaped" (did not recognize autologous virus).
  • 16 responses (from 14 participants) were non-escaped and highly proliferative.
• Cytotoxicity: Of the 14 participants with non-escaped, proliferative responses, 10 (17% of the total cohort) demonstrated recall cytotoxicity (measured by EASEA AUC) exceeding the first quartile of spontaneous controllers.
• Durability: Longitudinal analysis (median 2.6 years) confirmed that this high cytolytic potential is stably maintained during continuous ART.

B. Association with HIV-1 Reservoir

Participants with high recall cytotoxicity harbored significantly smaller reservoirs compared to those with poor function:

• Total HIV-1 DNA: Mean 85 vs. 254 copies/10⁶ PBMCs.
• Intact HIV-1 DNA: Mean 3.9 vs. 32.3 copies/10⁶ PBMCs.
• Cell-associated usRNA (Transcriptional Activity): Mean 130 vs. 751 copies/10⁶ PBMCs ($p=0.03$).
• Note: No significant associations were found with pre-ART disease progression (peak viral load or CD4 nadir), suggesting the functional immunity is not merely a result of milder initial infection.

C. Dynamics During Analytical Treatment Interruption (Participant H047)

• Viral Kinetics: Viral rebound occurred by week 2, peaked at week 5 ($5.16 \log_{10}$), and spontaneously dropped 3.9-fold by week 6 (prior to ART restart).
• Immune Expansion:
  • NK Cells: Expanded 1.7–1.9-fold starting week 2.
  • CD8+ T Cells: A specific subcluster (Cluster 2) expanded 7–8-fold starting week 4.
  • Clonotypes: The dominant Gag-specific clonotype (CSARLRTSGHDSTDTQYF) expanded 2.7-fold in vivo, mirroring its in vitro proliferation capacity.
• Attenuation Mechanism: The rapid reduction in viremia coincided with the in vivo expansion and differentiation of Gag-specific CD8+ T cells (increased CD38, HLA-DR, Perforin, Granzyme B).
• Clonal Diversity: Two distinct clonotypes expanded in parallel:
  1. Dominant Clonotype: Phenotypically "progenitor-exhausted" (PD-1+, TIGIT+, TOX+, TCF-1+).
  2. Subdominant Clonotype: Phenotypically "quiescent" (CD226+, TCF-7+).
  • Both expanded similarly and acquired cytotoxic effector functions, indicating that functional capacity is not restricted to a single phenotypic state.

5. Significance and Implications

• Redefining Immune Control: The study challenges the dogma that CD8+ T cell function is irreversibly lost in chronic HIV infection. A substantial minority (17%) of treated individuals retain "elite" immune functionality capable of targeting the reservoir.
• Therapeutic Targets: The finding that recall cytotoxicity correlates with smaller reservoirs and attenuates rebound suggests that immunotherapeutic strategies should focus on:
  1. Restoring/Eliciting these specific recall cytotoxic responses in the remaining 83% of patients.
  2. Accelerating the recall response (e.g., via therapeutic vaccination) to bridge the gap between viral rebound and ART re-initiation.
• Biomarker Refinement: The study highlights that phenotypic markers (e.g., PD-1 expression) alone are insufficient to predict function. Functional profiling against autologous epitopes is critical, as mutational escape can mask functional potential if only consensus peptides are used.
• Path to Remission: While recall cytotoxicity alone was insufficient to prevent rebound in the ATI case, its role in limiting rebound magnitude supports a multimodal cure strategy combining latency reversal, reservoir reduction, and immune boosting to achieve durable ART-free remission.